Showing results (1-10 of 175) with videos related to

Sort By:
Pageof 18
Best Practice & Research. Clinical Rheumatology|January 24, 2012
Adaptive immunity in rheumatic diseases: bystander or pathogenic player?Hans Ulrich Scherer, Gerd-Rüdiger Burmester
Clinical Immunology (Orlando, Fla.)|August 1, 2016
The proteasome - victim or culprit in autoimmunityEugen Feist, Gerd-Rüdiger Burmester, Elke Krüger
Current Opinion in Rheumatology|February 25, 2011
Heparin or aspirin or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome)Berthold Hoppe, Gerd-Rüdiger Burmester, Thomas Dörner
Deutsches Arzteblatt International|July 7, 2009
The serological diagnosis of rheumatoid arthritis: antibodies to citrullinated antigensKarl Egerer, Eugen Feist, Gerd-Rüdiger Burmester
Lancet (London, England)|March 1, 2005
Optimised glucocorticoid therapy: the sharpening of an old spearFrank Buttgereit, Gerd-Rüdiger Burmester, Brian J Lipworth
Zeitschrift Fur Rheumatologie|September 1, 2023
[Therapeutic antibodies in rheumatology]Fredrik N Albach, Gerd-Rüdiger Burmester, Johanna Mucke
Therapeutic Advances in Musculoskeletal Disease|October 18, 2021
The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritisAli Berkant Avci, Eugen Feist, Gerd Rüdiger Burmester
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 30, 2018
Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?Ali Berkant Avci, Eugen Feist, Gerd Rüdiger Burmester
Clinical and Experimental Rheumatology|September 3, 2016
Targeting GM-CSF in rheumatoid arthritisAli Berkant Avci, Eugen Feist, Gerd-Rüdiger Burmester
Deutsches Arzteblatt International|December 17, 2021
The Safety of Antirheumatic DrugsJohanna Mucke, Hans-Uwe Simon, Gerd Rüdiger Burmester
Pageof 18